This is a table of type bigram and their frequencies. Use it to search & browse the list to learn more about your study carrel.
bigram | frequency |
---|---|
nucleic acid | 2392 |
gene expression | 2269 |
immune response | 1777 |
amino acid | 1728 |
cell lines | 1694 |
immune responses | 1570 |
amino acids | 1439 |
blood donors | 1156 |
breast cancer | 1108 |
dna vaccine | 1106 |
cell line | 1087 |
nucleic acids | 1065 |
dna damage | 1031 |
stem cells | 997 |
time pcr | 990 |
cell death | 961 |
dna vaccines | 961 |
flow cytometry | 954 |
whole blood | 943 |
cell cycle | 936 |
immune system | 931 |
type i | 929 |
mg kg | 921 |
viral dna | 905 |
gene therapy | 889 |
cancer cells | 883 |
bone marrow | 878 |
virus infection | 840 |
present study | 836 |
oxidative stress | 836 |
innate immune | 834 |
rna viruses | 830 |
blood transfusion | 825 |
escherichia coli | 818 |
dna polymerase | 797 |
chain reaction | 795 |
infectious diseases | 789 |
influenza virus | 775 |
stem cell | 771 |
infected cells | 769 |
clinical trials | 761 |
epithelial cells | 759 |
control group | 756 |
significantly higher | 756 |
polymerase chain | 749 |
red blood | 748 |
protein expression | 735 |
cell culture | 735 |
important role | 732 |
dendritic cells | 730 |
plasmid dna | 728 |
ng ml | 728 |
acute respiratory | 723 |
performed using | 719 |
hbv dna | 696 |
respiratory syndrome | 691 |
stranded dna | 690 |
dna sequences | 688 |
prostate cancer | 680 |
genomic dna | 674 |
immunodeficiency virus | 667 |
cell proliferation | 661 |
tumor cells | 652 |
isothermal amplification | 649 |
doc id | 647 |
cord uid | 647 |
results suggest | 639 |
rna polymerase | 637 |
herpes simplex | 631 |
vaccinia virus | 626 |
cell surface | 626 |
western blot | 626 |
blood samples | 623 |
dna replication | 622 |
blood cells | 622 |
virus type | 616 |
growth factor | 614 |
study design | 614 |
peripheral blood | 608 |
cystic fibrosis | 605 |
extracellular vesicles | 604 |
host cell | 596 |
class i | 595 |
electron microscopy | 590 |
human immunodeficiency | 580 |
simplex virus | 580 |
transcription factor | 576 |
viral replication | 572 |
dna viruses | 571 |
summary conclusion | 570 |
chronic hepatitis | 568 |
mass spectrometry | 565 |
severe acute | 560 |
blood components | 559 |
viral rna | 558 |
virus replication | 557 |
significant difference | 551 |
target dna | 542 |
blood donation | 541 |
cell types | 540 |
dna sequence | 537 |
reverse transcription | 536 |
endothelial cells | 536 |
statistically significant | 523 |
lymph nodes | 522 |
lymph node | 521 |
blood products | 520 |
plasma membrane | 515 |
human genome | 510 |
may also | 506 |
gene transfer | 504 |
case studies | 502 |
transcription factors | 498 |
mg ml | 497 |
summary conclusions | 490 |
blood group | 486 |
red cell | 485 |
background case | 481 |
widely used | 481 |
cell responses | 478 |
two different | 476 |
significant differences | 476 |
binding site | 475 |
risk factors | 474 |
mg dl | 473 |
molecular weight | 470 |
wild type | 467 |
public health | 463 |
monoclonal antibodies | 461 |
dna methylation | 460 |
wide range | 460 |
mammalian cells | 459 |
liver failure | 453 |
cancer cell | 452 |
drug delivery | 451 |
mediated isothermal | 448 |
reverse transcriptase | 447 |
dna repair | 447 |
room temperature | 447 |
nervous system | 444 |
viral infection | 442 |
respiratory tract | 441 |
binding protein | 441 |
results indicate | 439 |
viral infections | 437 |
smooth muscle | 436 |
binding sites | 432 |
gene delivery | 429 |
cd cd | 429 |
large number | 421 |
viral proteins | 421 |
side effects | 418 |
blood bank | 418 |
first time | 416 |
expression levels | 415 |
mean age | 412 |
high levels | 406 |
monoclonal antibody | 404 |
hepatocellular carcinoma | 402 |
data suggest | 399 |
blood cell | 399 |
united states | 398 |
secondary structure | 397 |
mouse model | 397 |
pg ml | 396 |
design method | 391 |
host cells | 391 |
commercially available | 388 |
viral genome | 388 |
commonly used | 388 |
two groups | 386 |
pregnant women | 384 |
dependent manner | 383 |
previous studies | 383 |
gel electrophoresis | 380 |
molecular mechanisms | 379 |
staphylococcus aureus | 379 |
lung cancer | 376 |
gold nanoparticles | 376 |
active site | 375 |
results finding | 375 |
mrna expression | 374 |
quality control | 372 |
stranded rna | 371 |
copy number | 371 |
colorectal cancer | 370 |
infectious disease | 368 |
significantly increased | 367 |
protein kinase | 364 |
results show | 363 |
clinical signs | 363 |
clinical samples | 357 |
determine whether | 354 |
cell growth | 352 |
dna binding | 351 |
molecular biology | 350 |
real time | 348 |
antiviral activity | 347 |
dna vaccination | 347 |
generation sequencing | 346 |
previously described | 345 |
vaccine development | 345 |
innate immunity | 345 |
transfusion medicine | 345 |
animal models | 344 |
years old | 344 |
results showed | 343 |
cell carcinoma | 341 |
closely related | 338 |
recent years | 336 |
blood pressure | 336 |
human papillomavirus | 335 |
viral load | 334 |
mycobacterium tuberculosis | 333 |
protein synthesis | 332 |
acid sequence | 332 |
significantly lower | 331 |
significant increase | 331 |
iu ml | 327 |
immune cells | 320 |
previously reported | 320 |
signal transduction | 320 |
mhc class | 320 |
rapid detection | 320 |
adverse events | 319 |
barr virus | 318 |
heat shock | 317 |
central nervous | 317 |
recent studies | 317 |
liver disease | 315 |
cell membrane | 315 |
inflammatory response | 315 |
rna virus | 314 |
pcr assay | 314 |
cell cultures | 313 |
clinical trial | 313 |
least one | 312 |
blood donor | 311 |
body weight | 310 |
target cells | 310 |
crystal structure | 309 |
dengue virus | 309 |
statistical analysis | 307 |
different types | 307 |
like receptor | 306 |
hbv infection | 304 |
reactive oxygen | 304 |
high affinity | 304 |
specific antibodies | 303 |
cd cells | 300 |
differential diagnosis | 299 |
cancer patients | 298 |
nk cells | 298 |
ex vivo | 298 |
significantly reduced | 297 |
detection limit | 297 |
i ifn | 296 |
virus particles | 296 |
dna synthesis | 295 |
ebola virus | 295 |
oxygen species | 295 |
transgenic mice | 295 |
endoplasmic reticulum | 293 |
signaling pathways | 293 |
surface plasmon | 293 |
dna sequencing | 292 |
neutralizing antibodies | 292 |
one patient | 290 |
red cells | 289 |
molecular dynamics | 286 |
pcr amplification | 286 |
dna amplification | 285 |
delivery systems | 285 |
biological activity | 285 |
antibiotic resistance | 285 |
syndrome coronavirus | 284 |
type ii | 284 |
binding proteins | 284 |
serum samples | 283 |
viral vectors | 283 |
phase i | 280 |
drug resistance | 280 |
analysis revealed | 279 |
quantitative pcr | 278 |
cell activation | 278 |
taken together | 278 |
western blotting | 278 |
blot analysis | 277 |
sequence analysis | 275 |
protein interactions | 274 |
plasmon resonance | 274 |
nitric oxide | 273 |
highly conserved | 273 |
antibody responses | 272 |
platelet count | 271 |
class ii | 271 |
even though | 270 |
pseudomonas aeruginosa | 269 |
also known | 268 |
dna extraction | 266 |
case report | 264 |
last years | 264 |
signaling pathway | 263 |
healthy controls | 263 |
risk factor | 263 |
also observed | 262 |
three different | 262 |
cell type | 262 |
sample preparation | 261 |
university hospital | 261 |
may contribute | 261 |
single nucleotide | 260 |
respiratory syncytial | 259 |
high throughput | 258 |
membrane protein | 257 |
cell receptor | 257 |
human cells | 257 |
platelet concentrates | 256 |
results obtained | 256 |
dna fragments | 256 |
copies ml | 256 |
may play | 256 |
binding domain | 254 |
significantly different | 254 |
pcr products | 253 |
increased risk | 252 |
cell viability | 251 |
also found | 251 |
syncytial virus | 251 |
genome sequence | 251 |
may provide | 250 |
highly sensitive | 249 |
year old | 248 |
antiviral therapy | 248 |
antibody response | 247 |
open reading | 247 |
transfusion reactions | 247 |
i interferon | 246 |
medical center | 246 |
adenovirus type | 244 |
situ hybridization | 244 |
may lead | 244 |
analyzed using | 243 |
high level | 242 |
homologous recombination | 241 |
differentially expressed | 240 |
autoimmune diseases | 240 |
life cycle | 239 |
conformational changes | 239 |
solid phase | 238 |
high sensitivity | 238 |
fold increase | 237 |
living cells | 236 |
lung disease | 236 |
human cytomegalovirus | 236 |
membrane proteins | 236 |
fever virus | 235 |
extracellular matrix | 235 |
determined using | 234 |
viral protein | 234 |
inflammatory cytokines | 234 |
nucleotide sequence | 233 |
viral genomes | 233 |
median age | 232 |
graphene oxide | 232 |
key role | 232 |
heart failure | 231 |
next generation | 231 |
mononuclear cells | 230 |
hematopoietic stem | 230 |
mrna levels | 229 |
recombinant protein | 229 |
analysis showed | 227 |
fusion protein | 227 |
rna interference | 227 |
adaptive immune | 226 |
specific cd | 225 |
wound healing | 225 |
blood supply | 223 |
viral gene | 223 |
lupus erythematosus | 223 |
crispr cas | 222 |
host immune | 222 |
positive control | 222 |
mesenchymal stem | 222 |
terminal domain | 222 |
small molecules | 221 |
hcv rna | 221 |
outer membrane | 221 |
low levels | 220 |
negative control | 220 |
acid amplification | 220 |
total rna | 219 |
treated cells | 219 |
muscle cells | 219 |
delivery system | 219 |
time points | 219 |
plasma samples | 219 |
acid residues | 219 |
squamous cell | 218 |
skeletal muscle | 218 |
clinical practice | 218 |
tumor cell | 216 |
expression level | 216 |
dna molecules | 216 |
protein levels | 215 |
positive results | 215 |
data indicate | 215 |
high risk | 215 |
whole genome | 215 |
ovarian cancer | 215 |
necrosis factor | 215 |
human adenovirus | 214 |
critical role | 214 |
measured using | 214 |
like particles | 214 |
significantly decreased | 214 |
virus dna | 213 |
mosaic virus | 213 |
data analysis | 213 |
dna aptamers | 212 |
cell adhesion | 212 |
first step | 212 |
graphical representation | 212 |
protective immunity | 212 |
diabetes mellitus | 211 |
deficient mice | 211 |
pcr assays | 211 |
multiple sclerosis | 211 |
base pairs | 210 |
tumor growth | 210 |
systemic lupus | 210 |
transfusion service | 210 |
structural proteins | 210 |
spinal cord | 210 |
total number | 209 |
blood banks | 209 |
also used | 209 |
reading frame | 209 |
cellular immune | 209 |
transgene expression | 209 |
cytosolic dna | 209 |
genetic material | 208 |
patients treated | 208 |
single cell | 208 |
findings suggest | 207 |
fatty acid | 207 |
specific dna | 207 |
positive cells | 207 |
presenting cells | 207 |
inhibitory effect | 207 |
wide variety | 207 |
nucleocapsid protein | 206 |
small molecule | 205 |
adverse effects | 205 |
sars coronavirus | 205 |
cycle arrest | 204 |
cells expressing | 204 |
naturally occurring | 204 |
infectious agents | 203 |
intensive care | 202 |
dna virus | 202 |
recent study | 201 |
growth factors | 201 |
positive samples | 201 |
analysis using | 201 |
west nile | 200 |
patients undergoing | 200 |
zika virus | 200 |
gastrointestinal tract | 200 |
blood collection | 199 |
lg ml | 199 |
disease virus | 199 |
negatively charged | 199 |
capsid protein | 199 |
blood donations | 199 |
fatty acids | 199 |
recent advances | 199 |
fold higher | 198 |
health care | 197 |
tumor suppressor | 197 |
years ago | 197 |
ms ms | 197 |
viral particles | 196 |
mitochondrial dna | 196 |
tissue culture | 196 |
crucial role | 196 |
results demonstrate | 195 |
old female | 195 |
rna molecules | 195 |
well known | 194 |
several studies | 193 |
family members | 193 |
long term | 193 |
may cause | 193 |
culture medium | 193 |
cells using | 192 |
surface antigen | 192 |
resistance genes | 191 |
like receptors | 191 |
cell response | 191 |
animal model | 191 |
specific antibody | 191 |
clinical studies | 190 |
introduction background | 190 |
significant reduction | 190 |
protein sequences | 189 |
three times | 189 |
two patients | 188 |
one case | 188 |
hela cells | 188 |
dna microarray | 187 |
specific primers | 187 |
avian influenza | 187 |
enzyme activity | 187 |
sting pathway | 187 |
based detection | 186 |
genes involved | 186 |
cell transplantation | 186 |
may result | 186 |
acid sequences | 186 |
epithelial cell | 185 |
virus detection | 185 |
studies showed | 185 |
expression vector | 185 |
genome sequencing | 184 |
multiplex pcr | 184 |
hiv infection | 184 |
factor viii | 184 |
cell wall | 184 |
based vaccines | 183 |
spike protein | 183 |
liver transplantation | 183 |
phylogenetic analysis | 183 |
preliminary results | 183 |
cell lymphoma | 183 |
cervical cancer | 182 |
antigen presentation | 182 |
cfu ml | 182 |
virus infections | 182 |
blood units | 182 |
neutralizing antibody | 182 |
highly specific | 182 |
current study | 182 |
dna sensing | 181 |
genetic information | 181 |
novel coronavirus | 181 |
old male | 181 |
protein complexes | 181 |
signal amplification | 181 |
human serum | 181 |
blood center | 180 |
increased expression | 180 |
exome sequencing | 180 |
per year | 180 |
enzymatic activity | 180 |
target genes | 180 |
antimicrobial resistance | 180 |
primary immunodeficiency | 179 |
tumor necrosis | 179 |
another study | 179 |
agarose gel | 178 |
data show | 178 |
energy transfer | 178 |
bacterial infections | 178 |
dna detection | 178 |
colon cancer | 178 |
transmission electron | 177 |
better understanding | 177 |
bovine serum | 177 |
tract infections | 177 |
mouse models | 176 |
gene silencing | 176 |
patients received | 176 |
negative bacteria | 176 |
cells infected | 176 |
two types | 176 |
clinical specimens | 175 |
target sequence | 175 |
serum levels | 173 |
protein structure | 173 |
cord blood | 173 |
disease progression | 173 |
lung injury | 173 |
influenza viruses | 172 |
dna samples | 172 |
vascular endothelial | 172 |
early stage | 172 |
humoral immune | 171 |
may occur | 171 |
higher levels | 171 |
antiviral drugs | 171 |
saccharomyces cerevisiae | 171 |
endothelial cell | 171 |
linked immunosorbent | 171 |
dependent rna | 170 |
sensitive detection | 170 |
binding affinity | 170 |
gene products | 170 |
cd expression | 170 |
standard deviation | 169 |
described previously | 169 |
simultaneous detection | 169 |
surface area | 169 |
poorly understood | 169 |
tissue samples | 168 |
nile virus | 168 |
clinical isolates | 168 |
type diabetes | 168 |
detection methods | 168 |
using different | 168 |
light scattering | 167 |
major role | 167 |
takes place | 167 |
swine fever | 167 |
blood safety | 167 |
fluorescence microscopy | 167 |
insulin resistance | 166 |
currently available | 166 |
based methods | 166 |
sanger sequencing | 166 |
drug discovery | 166 |
two cases | 165 |
clinically significant | 165 |
three patients | 165 |
live attenuated | 165 |
cell division | 165 |
will also | 165 |
viral diseases | 165 |
genomic rna | 165 |
magnetic beads | 164 |
tyrosine kinase | 164 |
also showed | 164 |
study period | 164 |
study showed | 164 |
days post | 164 |
genetic diversity | 164 |
free energy | 163 |
retrospective study | 163 |
recombinant proteins | 163 |
serum albumin | 163 |
gestational age | 163 |
cancer therapy | 163 |
overall survival | 163 |
single molecule | 162 |
lateral flow | 162 |
cytokine production | 162 |
human diseases | 162 |
bl mice | 162 |
one year | 162 |
circular dichroism | 162 |
antibody titers | 162 |
reporter gene | 162 |
gene encoding | 162 |
antimicrobial activity | 162 |
chronic inflammation | 162 |
proteins involved | 161 |
clinical features | 161 |
may represent | 161 |
cells treated | 161 |
positively charged | 161 |
topoisomerase i | 160 |
statistical significance | 160 |
lung function | 160 |
transfected cells | 160 |
pathogen detection | 160 |
dna microarrays | 160 |
inflammatory responses | 160 |
mediated gene | 160 |
expression patterns | 159 |
genes encoding | 159 |
point mutations | 159 |
target gene | 159 |
united kingdom | 159 |
immunosorbent assay | 159 |
hepg cells | 158 |
dna fragment | 158 |
protein production | 158 |
dna strand | 157 |
test results | 157 |
middle east | 157 |
blood product | 157 |
side chain | 157 |
fluorescent protein | 156 |
molecular mechanism | 156 |
sequence data | 156 |
small cell | 156 |
false positive | 156 |
protein sequence | 155 |
cell differentiation | 155 |
shock protein | 155 |
significant decrease | 155 |
patients without | 155 |
clinically relevant | 155 |
dendritic cell | 155 |
virus rna | 154 |
phase ii | 154 |
mm tris | 154 |
replacement therapy | 154 |
healthy individuals | 154 |
specific immune | 154 |
eukaryotic cells | 153 |
exclusion chromatography | 153 |
world health | 153 |
conformational change | 153 |
reading frames | 153 |
cellular processes | 153 |
samples collected | 153 |
high frequency | 153 |
induced apoptosis | 153 |
gene product | 153 |
immune complexes | 153 |
genetic variation | 152 |
dna aptamer | 152 |
bacterial contamination | 152 |
pcr product | 152 |
promoter region | 152 |
rheumatoid arthritis | 152 |
well tolerated | 152 |
future studies | 152 |
biological processes | 152 |
respiratory distress | 152 |
critically ill | 152 |
patients receiving | 151 |
core protein | 151 |
cell epitopes | 151 |
adipose tissue | 151 |
blood flow | 151 |
similar results | 150 |
antimicrobial peptides | 150 |
mast cells | 150 |
liquid chromatography | 150 |
hek cells | 150 |
clinical use | 150 |
molecular methods | 150 |
vaccine delivery | 150 |
dna helicase | 150 |
culture media | 150 |
leukemia virus | 150 |
high resolution | 150 |
different cell | 149 |
confocal microscopy | 149 |
evaluated using | 149 |
new insights | 149 |
protein folding | 149 |
cell function | 149 |
cells showed | 149 |
quantum dots | 149 |
lipid bilayer | 148 |
liver cirrhosis | 148 |
protein complex | 148 |
blood loss | 148 |
encephalitis virus | 148 |
many different | 148 |
cerebrospinal fluid | 148 |
flow cytometric | 148 |
three groups | 148 |
derived evs | 148 |
biologically active | 148 |
national institute | 148 |
early diagnosis | 147 |
antigen expression | 147 |
fluorescence intensity | 147 |
blood vessels | 147 |
rna synthesis | 147 |
strand rna | 147 |
model system | 147 |
virus genome | 146 |
study group | 146 |
will provide | 146 |
dna polymerases | 146 |
high specificity | 146 |
total protein | 146 |
rna genome | 146 |
molecular basis | 146 |
capillary electrophoresis | 146 |
viral pathogens | 146 |
much higher | 146 |
cell lung | 146 |
informed consent | 146 |
clinical diagnosis | 146 |
previously shown | 145 |
time rt | 145 |
atomic force | 145 |
nuclear factor | 145 |
results findings | 145 |
building blocks | 145 |
poor prognosis | 145 |
phage display | 145 |
infected patients | 145 |
essential role | 145 |
may help | 144 |
peptide synthesis | 144 |
two distinct | 144 |
vitro studies | 144 |
will allow | 144 |
fractal analysis | 144 |
design methods | 144 |
cell survival | 143 |
viral nucleic | 143 |
clinical data | 143 |
nucleotide sequences | 143 |
healthy donors | 143 |
clostridium difficile | 143 |
rabies virus | 143 |
least two | 143 |
immune deficiency | 143 |
chronic liver | 143 |
clinical microbiology | 143 |
nanoparticle tracking | 143 |
stress response | 143 |
authors declare | 142 |
nested pcr | 142 |
autoimmune disease | 142 |
present work | 142 |
hydrogen bonds | 142 |
weight loss | 142 |
damage response | 142 |
cell migration | 142 |
fi rst | 142 |
disease severity | 141 |
electrochemical detection | 141 |
great potential | 141 |
blood services | 141 |
nucleotide polymorphisms | 141 |
bowel disease | 141 |
transfection efficiency | 141 |
intermittent fasting | 140 |
tracking analysis | 140 |
small interfering | 140 |
significantly associated | 140 |
experimental data | 140 |
target cell | 140 |
small number | 140 |
secondary structures | 140 |
infected mice | 140 |
old woman | 140 |
human disease | 140 |
stromal cells | 139 |
dna sensor | 139 |
logistic regression | 139 |
urinary tract | 139 |
septic shock | 139 |
biofilm formation | 139 |
gold nanoparticle | 139 |
helicase activity | 139 |
side chains | 138 |
tissue damage | 138 |
viral genes | 138 |
rrna gene | 138 |
dnase i | 138 |
large scale | 138 |
airway epithelial | 137 |
natural killer | 137 |
prospective study | 137 |
blood mononuclear | 137 |
genome sequences | 137 |
brain barrier | 137 |
see table | 137 |
human health | 137 |
coding sequence | 137 |
dna encoding | 137 |
health organization | 137 |
cellular uptake | 137 |
mutation rate | 137 |
new york | 137 |
strand breaks | 137 |
hydrogen peroxide | 137 |
associated virus | 136 |
broad spectrum | 136 |
quantitative real | 136 |
recombinase polymerase | 136 |
potential therapeutic | 136 |
dna levels | 136 |
using two | 136 |
human dna | 136 |
alkaline phosphatase | 136 |
low molecular | 136 |
atpase activity | 136 |
full length | 136 |
acid extraction | 135 |
specific binding | 135 |
embryonic stem | 135 |
vesicular stomatitis | 135 |
positive correlation | 135 |
catalytic activity | 135 |
high prevalence | 135 |
molecular level | 134 |
sequence alignment | 134 |
drinking water | 134 |
tumour cells | 134 |
regression analysis | 134 |
drug development | 134 |
protein binding | 134 |
detection system | 134 |
polymerase amplification | 134 |
endothelial growth | 133 |
pcr using | 133 |
fecal samples | 133 |
cell membranes | 133 |
gene transcription | 133 |
sickle cell | 133 |
group i | 133 |
limited number | 133 |
based assays | 133 |
inflammatory bowel | 133 |
human blood | 133 |
diagnostic tests | 133 |
better understand | 132 |
four different | 132 |
times higher | 132 |
significant changes | 132 |
apoptotic cells | 132 |
er stress | 132 |
emerging infectious | 132 |
rolling circle | 132 |
developing countries | 132 |
studies using | 132 |
important roles | 132 |
take place | 132 |
african swine | 131 |
high degree | 131 |
cell populations | 131 |
transplant recipients | 131 |
early detection | 131 |
autosomal recessive | 131 |
binding rate | 131 |
bacterial infection | 131 |
th century | 131 |
two major | 131 |
gold standard | 131 |
ml min | 130 |
transfusion services | 130 |
platelet aggregation | 130 |
size exclusion | 130 |
clinical symptoms | 130 |
complete genome | 130 |
increased levels | 130 |
lentiviral vector | 130 |
force microscopy | 130 |
potential role | 130 |
protein microarrays | 130 |
circular dna | 130 |
binding activity | 130 |
expression system | 130 |
small intestine | 130 |
cells via | 130 |
cellular dna | 129 |
neurodegenerative diseases | 129 |
fusion proteins | 129 |
connective tissue | 129 |
adenoviral vectors | 129 |
mammalian cell | 129 |
combined immunodeficiency | 129 |
protein function | 129 |
may affect | 129 |
dynamics simulations | 129 |
biopsy specimens | 129 |
protein interaction | 128 |
mice immunized | 128 |
tritrichomonas foetus | 128 |
clinical outcome | 128 |
well established | 128 |
major histocompatibility | 128 |
also performed | 128 |
expression profiles | 128 |
ubiquitin ligase | 128 |
liver function | 128 |
canine parvovirus | 128 |
vaccine candidates | 128 |
healthy volunteers | 128 |
target protein | 127 |
respiratory infections | 127 |
coding region | 127 |
previous study | 127 |
age group | 127 |
rbc units | 127 |
capsid proteins | 127 |
time point | 127 |
structural basis | 127 |
predictive value | 127 |
cells may | 127 |
dna probes | 126 |
data sets | 126 |
hcv infection | 126 |
cell lysates | 126 |
relatively high | 126 |
detection using | 126 |
particle size | 126 |
causative agent | 126 |
neutrophil extracellular | 126 |
therapeutic potential | 126 |
affinity chromatography | 126 |
carbon nanotubes | 126 |
detected using | 126 |
thymidine kinase | 125 |
respiratory viruses | 125 |
positive patients | 125 |
adult patients | 125 |
relatively low | 125 |
control groups | 125 |
east respiratory | 125 |
streptococcus pneumoniae | 125 |
clinical manifestations | 125 |
pcr reaction | 125 |
polymerase ii | 125 |
affi nity | 125 |
past years | 125 |
soft tissue | 125 |
nuclear localization | 124 |
myocardial infarction | 124 |
cycle progression | 124 |
clinical course | 124 |
large amounts | 124 |
molecular diagnostics | 124 |
protein level | 124 |
remains unclear | 124 |
gene sequences | 124 |
primary human | 124 |
assessed using | 124 |
microarray technology | 124 |
reaction mixture | 124 |
healthy subjects | 124 |
blood component | 123 |
based assay | 123 |
early stages | 123 |
will help | 123 |
genetic analysis | 123 |
japanese encephalitis | 123 |
genetic engineering | 123 |
infected cell | 123 |
surface expression | 123 |
envelope protein | 123 |
dna complexes | 123 |
nk cell | 123 |
new approach | 123 |
kg day | 123 |
antibiotic therapy | 122 |
human herpesvirus | 122 |
year period | 122 |
family history | 122 |
care unit | 122 |
circle amplification | 122 |
plasma cells | 122 |
evidence suggests | 122 |
dna rna | 121 |
crystal structures | 121 |
human plasma | 121 |
ca i | 121 |
pcr analysis | 121 |
stomatitis virus | 121 |
therapeutic agents | 121 |
pluripotent stem | 121 |
significant correlation | 121 |
immune cell | 120 |
magnetic resonance | 120 |
based amplification | 120 |
vast majority | 120 |
data obtained | 120 |
membrane fusion | 120 |
vaccine vectors | 120 |
increasing number | 120 |
data demonstrate | 120 |
zinc finger | 120 |
antibody screening | 120 |
factor receptor | 120 |
dna delivery | 120 |
resonance energy | 120 |
vero cells | 120 |
terminal region | 119 |
associated protein | 119 |
well plates | 119 |
using dna | 119 |
ill patients | 119 |
central role | 119 |
give rise | 119 |
also shown | 119 |
applied biosystems | 119 |
gene regulation | 119 |
biological samples | 119 |
autologous blood | 119 |
preliminary data | 119 |
porcine circovirus | 119 |
structural changes | 119 |
two main | 119 |
plant viruses | 119 |
within hours | 119 |
adverse reactions | 119 |
combination therapy | 119 |
fresh frozen | 119 |
plasmodium falciparum | 119 |
activated protein | 119 |
liver injury | 119 |
antibiotic treatment | 119 |
catalytic domain | 119 |
inhibitory activity | 118 |
risk assessment | 118 |
ligand binding | 118 |
dna strands | 118 |
small rna | 118 |
regulatory factor | 118 |
studies revealed | 118 |
national blood | 118 |
birth weight | 118 |
low cost | 118 |
membrane potential | 118 |
breast carcinoma | 118 |
host defense | 118 |
synthetic peptides | 118 |
low level | 118 |
liver biopsy | 118 |
survival rate | 118 |
rate coefficient | 117 |
free radicals | 117 |
clinical significance | 117 |
resistant strains | 117 |
clinical applications | 117 |
cell biology | 117 |
amplification assay | 117 |
listeria monocytogenes | 117 |
speci fi | 117 |
chronic inflammatory | 117 |
negative results | 117 |
enveloped viruses | 117 |
infectious virus | 117 |
mouth disease | 117 |
lamina propria | 117 |
large numbers | 117 |
size distribution | 117 |
senescent cells | 117 |
influenza vaccine | 117 |
cell counts | 117 |
mortality rate | 117 |
inflammatory diseases | 117 |
patient samples | 117 |
chlamydia pneumoniae | 117 |
general population | 116 |
cardiac surgery | 116 |
throughput sequencing | 116 |
frozen plasma | 116 |
synthetic biology | 116 |
dna hybridization | 116 |
cell count | 116 |
broad range | 116 |
receptor binding | 116 |
high concentrations | 116 |
messenger rna | 116 |
rna polymerases | 116 |
lactic acid | 116 |
results indicated | 116 |
normal human | 116 |
umbilical cord | 116 |
showed significant | 116 |
antibody production | 115 |
plasma levels | 115 |
chitosan nanoparticles | 115 |
studies suggest | 115 |
different stages | 115 |
long time | 115 |
hepatitis virus | 115 |
study aimed | 115 |
vitro selection | 115 |
host range | 115 |
nlrp inflammasome | 114 |
expression pattern | 114 |
systematic review | 114 |
nuclear import | 114 |
mediated immune | 114 |
body mass | 114 |
may serve | 114 |
pancreatic cancer | 114 |
thermo fisher | 114 |
allowed us | 114 |
among others | 114 |
pathogenic bacteria | 114 |
different methods | 114 |
molecular detection | 114 |
vaccine candidate | 114 |
last decade | 114 |
genetically engineered | 114 |
genetic testing | 113 |
old man | 113 |
ribosomal rna | 113 |
electron transfer | 113 |
naked dna | 113 |
genome editing | 113 |
mechanisms underlying | 113 |
antiglobulin test | 113 |
target proteins | 113 |
two years | 113 |
lung tissue | 113 |
strand displacement | 113 |
based vaccine | 113 |
based dna | 112 |
brain tissue | 112 |
increased significantly | 112 |
cells transfected | 112 |
successfully used | 112 |
knockout mice | 112 |
expression profile | 112 |
dna template | 112 |
diagnostic methods | 112 |
amplification method | 112 |
age years | 112 |
proinflammatory cytokines | 112 |
dna probe | 112 |
also reported | 112 |
within days | 112 |
cho cells | 112 |
severe hepatitis | 112 |
structural protein | 112 |
interfering rna | 112 |
antigen presenting | 112 |
highly expressed | 112 |
complex formation | 112 |
patients showed | 111 |
abdominal pain | 111 |
rna sequencing | 111 |
hbv replication | 111 |
assay using | 111 |
apoptotic cell | 111 |
retrospective analysis | 111 |
mm nacl | 111 |
disease control | 111 |
powerful tool | 111 |
molecular recognition | 111 |
obtained using | 111 |
fractal dimension | 111 |
clinical presentation | 111 |
progenitor cells | 110 |
carcinoma cells | 110 |
shannon entropy | 110 |
extremely rare | 110 |
platelet activation | 110 |
physical examination | 110 |
virus vaccine | 110 |
measles virus | 110 |
diagnostic tools | 110 |
blood centers | 110 |
ionizing radiation | 110 |
free dna | 110 |
vaccine design | 110 |
ion channels | 110 |
newly synthesized | 110 |
one study | 110 |
protective effect | 110 |
recombinant human | 110 |
total dna | 110 |
investigate whether | 110 |
cmv dna | 109 |
paraffin embedded | 109 |
adaptive immunity | 109 |
creative commons | 109 |
per patient | 109 |
several different | 109 |
new therapeutic | 109 |
different concentrations | 109 |
synthetic dna | 109 |
fully automated | 109 |
oxidative damage | 109 |
human cancer | 109 |
cultured cells | 109 |
coding sequences | 109 |
expression vectors | 109 |
immunized mice | 109 |
analysed using | 108 |
positive controls | 108 |
data set | 108 |
tested using | 108 |
white blood | 108 |
studies will | 108 |
human breast | 108 |
cgas sting | 108 |
also demonstrated | 108 |
one hundred | 108 |
transcriptional regulation | 107 |
free radical | 107 |
recombinant vaccinia | 107 |
expression profiling | 107 |
molecular analysis | 107 |
mitochondrial membrane | 107 |
dna level | 107 |
rational design | 107 |
dna fragmentation | 107 |
medical university | 107 |
per day | 107 |
dna molecule | 107 |
pivotal role | 107 |
therapeutic targets | 107 |
metabolic syndrome | 107 |
distress syndrome | 107 |
viral vector | 107 |
renal failure | 107 |
sybr green | 107 |
refractive index | 107 |
infected individuals | 107 |
van der | 107 |
physiological conditions | 107 |
dna copies | 106 |
inflammatory cells | 106 |
biological systems | 106 |
blood cultures | 106 |
promoter activity | 106 |
recently reported | 106 |
bacterial dna | 106 |
dna double | 106 |
high dose | 106 |
microfluidic devices | 106 |
possible role | 106 |
nkt cells | 106 |
whole exome | 106 |
supplementary table | 106 |
general hospital | 106 |
chb patients | 106 |
free survival | 106 |
tested positive | 105 |
donor selection | 105 |
among patients | 105 |
study shows | 105 |
cardiovascular disease | 105 |
antiviral response | 105 |
age groups | 105 |
expression analysis | 105 |
dna using | 105 |
heart disease | 105 |
host species | 105 |
single dose | 105 |
tissue sections | 105 |
yersinia pestis | 105 |
respiratory disease | 105 |
i molecules | 105 |
coronary artery | 105 |
therapeutic target | 105 |
method using | 105 |
lipid bilayers | 105 |
antiviral agents | 105 |
bacterial growth | 105 |
intrinsically disordered | 105 |
histocompatibility complex | 104 |
extracellular traps | 104 |
chemical synthesis | 104 |
therapeutic strategies | 104 |
often used | 104 |
modifi ed | 104 |
final concentration | 104 |
i ii | 104 |
immunohistochemical staining | 104 |
vivo studies | 104 |
standard curve | 104 |
viral antigens | 104 |
much lower | 104 |
genome size | 104 |
high expression | 104 |
human igg | 104 |
quantitative analysis | 103 |
control cells | 103 |
throughput screening | 103 |
cellular functions | 103 |
sequence similarity | 103 |
multivariate analysis | 103 |
life technologies | 103 |
accession number | 103 |
different species | 103 |
cell development | 103 |
blood service | 103 |
internal control | 103 |
biological functions | 103 |
many cases | 103 |
growth rate | 103 |
differential expression | 103 |
high quality | 103 |
alternative splicing | 103 |
pilot study | 103 |
two independent | 103 |
cell population | 102 |
programmed cell | 102 |
insect cells | 102 |
environmental factors | 102 |
bronchoalveolar lavage | 102 |
mutation rates | 102 |
upper respiratory | 102 |
leaf curl | 102 |
hla class | 102 |
lower respiratory | 102 |
kinase activity | 102 |
light chain | 102 |
pediatric patients | 102 |
rhesus macaques | 102 |
metal ions | 102 |
virulence factors | 102 |
rbc transfusion | 102 |
highly efficient | 102 |
drug design | 101 |
specific antigen | 101 |
positive bacteria | 101 |
virus evolution | 101 |
rna replication | 101 |
low concentrations | 101 |
drug administration | 101 |
biomedical applications | 101 |
base pair | 101 |
cellular immunity | 101 |
liver cancer | 101 |
bacterial pathogens | 101 |
specific pcr | 101 |
functional analysis | 101 |
lipid peroxidation | 101 |
detection method | 101 |
cohort study | 100 |
shock proteins | 100 |
bacterial species | 100 |
may explain | 100 |
uric acid | 100 |
lentiviral vectors | 100 |
red cross | 100 |
strains isolated | 100 |
infectious bronchitis | 100 |
coding regions | 100 |
also detected | 100 |
viral hepatitis | 100 |
complementary dna | 100 |
tissue engineering | 100 |
salmonella enterica | 100 |
adhesion molecule | 99 |
ascorbic acid | 99 |
serial dilutions | 99 |
three cases | 99 |
nonhuman primates | 99 |
nmr spectroscopy | 99 |
week intermittent | 99 |
diagnostic tool | 99 |
thermal cycling | 99 |
signalling pathways | 99 |
high grade | 99 |
blood groups | 99 |
showed high | 99 |
gastric cancer | 99 |
immunocompromised patients | 99 |
cellular proteins | 99 |
directed mutagenesis | 99 |
sequencing data | 99 |
igg antibodies | 99 |
monoclonal anti | 98 |
renal cell | 98 |
research institute | 98 |
acute liver | 98 |
reactive protein | 98 |
restriction enzyme | 98 |
immunohistochemical analysis | 98 |
phylogenetic tree | 98 |
first report | 98 |
per unit | 98 |
bladder cancer | 98 |
optical tweezers | 98 |
also tested | 98 |
cell carcinomas | 98 |
first case | 98 |
copy numbers | 98 |
blood volume | 98 |
inflammasome activation | 98 |
yellow fever | 97 |
excision repair | 97 |
rna aptamers | 97 |
much less | 97 |
normal range | 97 |
density gradient | 97 |
cancer progression | 97 |
molecular techniques | 97 |
copies per | 97 |
guinea pigs | 97 |
myeloid cells | 97 |
adhesion molecules | 97 |
point mutation | 97 |
nonstructural protein | 97 |
bacterial cells | 97 |
study included | 97 |
cell density | 97 |
identified using | 97 |
nanopore sequencing | 97 |
dna immunization | 97 |
oral administration | 97 |
elevated levels | 97 |
single stranded | 97 |
four patients | 97 |
host genome | 97 |
cell clones | 97 |
cmv infection | 97 |
patients suffering | 97 |
identifi ed | 97 |
tumor size | 96 |
large dna | 96 |
cpg sites | 96 |
protease inhibitors | 96 |
university medical | 96 |
chikungunya virus | 96 |
direct detection | 96 |
regulatory elements | 96 |
severe disease | 96 |
using pcr | 96 |
dna concentration | 96 |
superoxide dismutase | 96 |
czech republic | 96 |
samples using | 96 |
genetically modified | 96 |
pcr method | 96 |
structural analysis | 96 |
different time | 96 |
raman spectroscopy | 96 |
two weeks | 96 |
time consuming | 95 |
ulcerative colitis | 95 |
stool samples | 95 |
cell lysis | 95 |
currently used | 95 |
coupled receptors | 95 |
linear regression | 95 |
close proximity | 95 |
blood sample | 95 |
light microscopy | 95 |
vaccine encoding | 95 |
highly effective | 95 |
infl uenza | 95 |
epidemiological studies | 95 |
fluorescence detection | 95 |
angiotensin ii | 95 |
five patients | 95 |
natural products | 95 |
extraction methods | 95 |
expressing cells | 95 |
magnetic nanoparticles | 95 |
dna analysis | 95 |
viruses may | 95 |
platelet counts | 95 |
specific detection | 94 |
newcastle disease | 94 |
helicobacter pylori | 94 |
time quantitative | 94 |
histological examination | 94 |
salmonella typhimurium | 94 |
control subjects | 94 |
pulmonary disease | 94 |
viral sequences | 94 |
results demonstrated | 94 |
recently developed | 94 |
cell immune | 94 |
cancer treatment | 94 |
extracellular dna | 94 |
low dose | 94 |
platelet transfusion | 94 |
sequence information | 94 |
single cells | 94 |
hyaluronic acid | 94 |
blood culture | 94 |
acid detection | 94 |
persistent infection | 94 |
leading cause | 94 |
immune evasion | 94 |
fatty liver | 94 |
dose dependent | 93 |
cells ml | 93 |
polyethylene glycol | 93 |
membrane vesicles | 93 |
life sciences | 93 |
study demonstrates | 93 |
frequently used | 93 |
double stranded | 93 |
urine samples | 93 |
sample size | 93 |
negative controls | 93 |
well plate | 93 |
conventional pcr | 93 |
also present | 93 |
microscopic examination | 93 |
methods used | 93 |
substrate specificity | 93 |
fat diet | 93 |
control samples | 93 |
treated patients | 93 |
per well | 93 |
many studies | 92 |
new method | 92 |
new zealand | 92 |
play important | 92 |
severe combined | 92 |
national institutes | 92 |
viral entry | 92 |
colorectal carcinoma | 92 |
mediated immunity | 92 |
surface protein | 92 |
million people | 92 |
gene sequence | 92 |
group ii | 92 |
disease caused | 92 |
biological function | 92 |
human body | 92 |
patients underwent | 92 |
candidate genes | 92 |
double strand | 92 |
medical records | 92 |
lysis buffer | 92 |
expression systems | 92 |
sample collection | 91 |
fetal growth | 91 |
medical history | 91 |
rapid identification | 91 |
green fluorescent | 91 |
comparative analysis | 91 |
rat model | 91 |
high molecular | 91 |
cardiovascular diseases | 91 |
growth hormone | 91 |
normal cells | 91 |
cell therapy | 91 |
expressed genes | 91 |
virus isolation | 91 |
coding genes | 91 |
patients compared | 91 |
using standard | 91 |
using flow | 91 |
major cause | 91 |
secondary antibody | 91 |
interferon regulatory | 91 |
probably due | 91 |
isolated using | 91 |
recent developments | 91 |
mitochondrial dysfunction | 91 |
based biosensors | 91 |
quality assurance | 91 |
human cell | 91 |
pattern recognition | 91 |
tumor progression | 91 |
glucocorticoid receptor | 90 |
microarray analysis | 90 |
buffy coat | 90 |
induced dna | 90 |
receptor expression | 90 |
electrode surface | 90 |
investigated using | 90 |
cvid patients | 90 |
one week | 90 |
provide evidence | 90 |
among different | 90 |
might also | 90 |
ionic strength | 90 |
inhibitory effects | 90 |
bacillus anthracis | 90 |
six months | 90 |
low grade | 90 |
electrostatic interactions | 90 |
novel therapeutic | 90 |
com scientificreports | 90 |
pathogen inactivation | 90 |
high mortality | 89 |
induced pluripotent | 89 |
tract infection | 89 |
infl uence | 89 |
cellular senescence | 89 |
study revealed | 89 |
many viruses | 89 |
calculated using | 89 |
well understood | 89 |
usa introduction | 89 |
epidermal growth | 89 |
resonance imaging | 89 |
liver tissue | 89 |
image analysis | 89 |
previously published | 89 |
like protein | 89 |
target molecules | 89 |
binding domains | 89 |
recurrent infections | 89 |
microfluidic device | 89 |
sequence identity | 89 |
effective treatment | 89 |
lipid membranes | 89 |
per cell | 89 |
coding rnas | 89 |
functional groups | 89 |
acute phase | 89 |
genetic variants | 89 |
rna aptamer | 89 |
nuclear translocation | 88 |
healthy control | 88 |
protein structures | 88 |
cmv promoter | 88 |
herpes virus | 88 |
recombinant viruses | 88 |
inflammatory cytokine | 88 |
targeted delivery | 88 |
surface proteins | 88 |
surface markers | 88 |
bacillus subtilis | 88 |
false positives | 88 |
cancer stem | 88 |
rna sequences | 88 |
human lung | 88 |
infection control | 88 |
patient care | 88 |
polyacrylamide gel | 88 |
stop codon | 88 |
quantitative rt | 88 |
small size | 88 |
rna world | 88 |
heavy chain | 88 |
fungal infections | 88 |
human coronavirus | 87 |
product quality | 87 |
infections caused | 87 |
thermal stability | 87 |
protective immune | 87 |
data showed | 87 |
induced cell | 87 |
molecular patterns | 87 |
effector cells | 87 |
proteins may | 87 |
associated proteins | 87 |
concentration range | 87 |
treatment group | 87 |
heart rate | 87 |
replication cycle | 87 |
amplification reaction | 87 |
species identification | 87 |
also evaluated | 87 |
new class | 87 |
recombinant adenovirus | 87 |
three major | 87 |
therapeutic applications | 87 |
state university | 87 |
significant association | 86 |
nuclear antigen | 86 |
based method | 86 |
antibody screen | 86 |
significant role | 86 |
experimental conditions | 86 |
transfusion practice | 86 |
time period | 86 |
cell disease | 86 |
protein gene | 86 |
clinical outcomes | 86 |
serum hbv | 86 |
cell epitope | 86 |
mechanical properties | 86 |
quantified using | 86 |
prognostic factors | 86 |
first trimester | 86 |
local structures | 86 |
phase iii | 86 |
renal function | 86 |
high incidence | 86 |
randomly selected | 86 |
mg day | 86 |
ko mice | 86 |
health effects | 86 |
platelet function | 86 |
systemic inflammation | 86 |
studies show | 85 |
translational modifications | 85 |
high rate | 85 |
medium containing | 85 |
cells compared | 85 |
mm edta | 85 |
supplementary material | 85 |
university school | 85 |
antiviral drug | 85 |
genome replication | 85 |
genomic sequences | 85 |
steady state | 85 |
antimicrobial agents | 85 |
rna extraction | 85 |
clinical application | 85 |
whole cell | 85 |
machine learning | 85 |
th cells | 85 |
well characterized | 85 |
blood transfusions | 85 |
cellular responses | 85 |
patients may | 85 |
various types | 85 |
two methods | 85 |
second messenger | 85 |
immune dysregulation | 85 |
live cells | 84 |
neoplastic cells | 84 |
amniotic fluid | 84 |
mass index | 84 |
liver diseases | 84 |
viral antigen | 84 |
weight gain | 84 |
plasma concentrations | 84 |
blood glucose | 84 |
north america | 84 |
host dna | 84 |
effi cient | 84 |
master mix | 84 |
confidence interval | 84 |
wistar rats | 84 |
rna recombination | 84 |
first described | 83 |
converting enzyme | 83 |
cyclic gmp | 83 |
fisher scientific | 83 |
comet assay | 83 |
estrogen receptor | 83 |
cdna clones | 83 |
findings indicate | 83 |
hemorrhagic fever | 83 |
months later | 83 |
protease inhibitor | 83 |
foreign dna | 83 |
another example | 83 |
using high | 83 |
serine protease | 83 |
human clinical | 83 |
viral clearance | 83 |
virus ns | 83 |
cas system | 83 |
molecular mass | 83 |
amplifi cation | 83 |
library preparation | 83 |
previous work | 83 |
physicochemical properties | 83 |
inflammatory mediators | 83 |
associated herpesvirus | 83 |
vascular smooth | 83 |
gene amplification | 83 |
pulmonary function | 83 |
manufacturing process | 83 |
vivo gene | 83 |
way anova | 83 |
treated mice | 82 |
human cancers | 82 |
extracellular vesicle | 82 |
allow us | 82 |
syndrome virus | 82 |
ang ii | 82 |
study demonstrated | 82 |
samples obtained | 82 |
signalling pathway | 82 |
done using | 82 |
cd positive | 82 |
significant effect | 82 |
many years | 82 |
associated molecular | 82 |
cd cell | 82 |
susceptibility testing | 82 |
dna extracted | 82 |
examination revealed | 82 |
significantly improved | 82 |
useful tool | 82 |
murine model | 82 |
high concentration | 82 |
resistance mechanisms | 82 |
adaptor protein | 82 |
model systems | 82 |
nucleotide polymorphism | 82 |
dynamic light | 82 |
factors associated | 82 |
interfering rnas | 82 |
ns protein | 82 |
digital pcr | 82 |
animal species | 82 |
using real | 81 |
stimulating factor | 81 |
translation initiation | 81 |
pathogen reduction | 81 |
th week | 81 |
physical properties | 81 |
proteomic analysis | 81 |
will require | 81 |
additional file | 81 |
uv light | 81 |
target sequences | 81 |
environmental samples | 81 |
transfusion therapy | 81 |
results will | 81 |
turkey objective | 81 |
ns ns | 81 |
largely unknown | 81 |
hcv core | 81 |
first study | 81 |
fluorescence signal | 81 |
also investigated | 81 |
derived exosomes | 81 |
microfluidic systems | 81 |
hydrogen bonding | 81 |
sindbis virus | 81 |
like virus | 81 |
clinical disease | 81 |
potential use | 81 |
successfully applied | 81 |
prognostic factor | 81 |
rna binding | 81 |
noncoding rna | 81 |
mm mgcl | 81 |
medical school | 80 |
tertiary structure | 80 |
one single | 80 |
foreign gene | 80 |
developed using | 80 |
time donors | 80 |
chronic hbv | 80 |
protein degradation | 80 |
iron deficiency | 80 |
maternal plasma | 80 |
protein kinases | 80 |
pcr system | 80 |
assays using | 80 |
culture system | 80 |
acute lung | 80 |
structural features | 80 |
phase peptide | 80 |
specific gene | 80 |
i ifns | 80 |
positive result | 80 |
protective efficacy | 80 |
still unclear | 80 |
transcriptional activation | 80 |
controlled trial | 80 |
fetal dna | 80 |
studies indicate | 80 |
metabolic pathways | 80 |
fully understood | 80 |
newborn screening | 79 |
control mice | 79 |
lactate dehydrogenase | 79 |
salivary gland | 79 |
van een | 79 |
single strand | 79 |
next step | 79 |
six patients | 79 |
vaccine vector | 79 |
bat species | 79 |
samples tested | 79 |
serum igg | 79 |
natural history | 79 |
least three | 79 |
new generation | 79 |
will present | 79 |
somatic cells | 79 |
different mechanisms | 79 |
melanoma cells | 79 |
laboratory tests | 79 |
nad levels | 79 |
cpg motifs | 79 |
hemolytic anemia | 79 |
patients diagnosed | 79 |
adenovirus vectors | 79 |
female donors | 79 |
influenza vaccines | 79 |
achieved using | 79 |
novel approach | 79 |
provide new | 79 |
three months | 79 |
type mice | 79 |
group system | 79 |
lamp reaction | 79 |
zoster virus | 79 |
data storage | 79 |
resistance gene | 79 |
trauma patients | 79 |
transcriptional activity | 79 |
protein content | 79 |
studied using | 78 |
also identified | 78 |
autosomal dominant | 78 |
blood plasma | 78 |
skin lesions | 78 |
highly selective | 78 |
dna load | 78 |
cell subsets | 78 |
recipient cells | 78 |
research center | 78 |
viral capsid | 78 |
human monocytes | 78 |
sle patients | 78 |
located within | 78 |
based approach | 78 |
human adenoviruses | 78 |
sequence homology | 78 |
sialic acid | 78 |
oligonucleotide probes | 78 |
antiviral treatment | 78 |
recently described | 78 |
also called | 78 |
may influence | 78 |
transfusion reaction | 78 |
cell entry | 78 |
current status | 78 |
three years | 78 |
based gene | 78 |
large amount | 78 |
transgenic mouse | 78 |
related genes | 78 |
virus genomes | 78 |
multidrug resistance | 78 |
amyloid fibrils | 78 |
novel method | 78 |
simian virus | 78 |
long noncoding | 78 |
specifi city | 78 |
san diego | 78 |
acid composition | 78 |
cells per | 78 |
recombinant dna | 77 |
bacterial cell | 77 |
buffered saline | 77 |
may induce | 77 |
gives rise | 77 |
solid support | 77 |
purified using | 77 |
human respiratory | 77 |
free detection | 77 |
spleen cells | 77 |
compared using | 77 |
subcellular localization | 77 |
mitochondrial function | 77 |
aqueous solution | 77 |
i will | 77 |
normalized shannon | 77 |
cellular rna | 77 |
horseradish peroxidase | 77 |
nude mice | 77 |
voluntary blood | 77 |
virus discovery | 77 |
two proteins | 77 |
protein coding | 77 |
health problem | 77 |
extraction method | 77 |
promising results | 77 |
ros production | 77 |
humoral immunity | 77 |
culture conditions | 77 |
negative patients | 77 |
fluorescence resonance | 77 |
human embryonic | 77 |
capture probe | 77 |
body fluids | 77 |
derived extracellular | 77 |
human skin | 77 |
clinical laboratory | 77 |
massive transfusion | 76 |
weeks gestation | 76 |
liver cells | 76 |
specific genes | 76 |
diabetic patients | 76 |
great interest | 76 |
tandem mass | 76 |
lower levels | 76 |
molecular cloning | 76 |
several years | 76 |
reported cases | 76 |
surface receptors | 76 |
also significantly | 76 |
significantly correlated | 76 |
young children | 76 |
comparative study | 76 |
higher risk | 76 |
analytical sensitivity | 76 |
higher sensitivity | 76 |
ic values | 76 |
es cells | 76 |
host disease | 76 |
culture supernatants | 76 |
living organisms | 76 |
donate blood | 76 |
human primates | 76 |
one another | 76 |
hospital stay | 76 |
ribosomal frameshifting | 76 |
methylene blue | 76 |
virus vectors | 76 |
molecular characterization | 76 |
western blots | 76 |
fluorescence spectroscopy | 76 |
kinase inhibitor | 76 |
dimensional structure | 76 |
immunodeficient mice | 76 |
solid tumors | 76 |
vaccine strain | 76 |
repetitive sequences | 76 |
high density | 75 |
previously demonstrated | 75 |
randomized controlled | 75 |
safe blood | 75 |
mechanisms involved | 75 |
neuronal cells | 75 |
yeast cells | 75 |
using either | 75 |
ef fi | 75 |
ms patients | 75 |
one hand | 75 |
igm antibodies | 75 |
coated magnetic | 75 |
blood banking | 75 |
different viruses | 75 |
molecular diagnostic | 75 |
liver damage | 75 |
science foundation | 75 |
nadph oxidase | 75 |
showed similar | 75 |
post infection | 75 |
biological activities | 75 |
drug targets | 75 |
dna sensors | 75 |
flow cytometer | 75 |
cellular response | 75 |
dna constructs | 75 |
proliferative activity | 75 |
fluorescently labeled | 75 |
binding properties | 75 |
may act | 75 |
obtained results | 75 |
treated animals | 75 |
murine leukemia | 75 |
cancer development | 74 |
amplification methods | 74 |
data support | 74 |
critical illness | 74 |
highly pathogenic | 74 |
treg cells | 74 |
clinical relevance | 74 |
molecular beacon | 74 |
scanning electron | 74 |
splice site | 74 |
noncoding rnas | 74 |
antisense oligonucleotides | 74 |
tissue factor | 74 |
terminal repeat | 74 |
natural infection | 74 |
chronic infection | 74 |
hemolytic transfusion | 74 |
gene mutations | 74 |
regulatory proteins | 74 |
recently identified | 74 |
capture probes | 74 |
luciferase reporter | 74 |
human viruses | 74 |
polyclonal antibodies | 74 |
antibodies specific | 74 |
important factor | 74 |
urinary bladder | 74 |
vitro transcription | 74 |
coat protein | 74 |
within min | 74 |
acid testing | 74 |
two days | 74 |
supplementary information | 74 |
human airway | 74 |
chinese hamster | 74 |
flow rate | 74 |
toxic effects | 74 |
virus challenge | 74 |
mice treated | 74 |
interacting protein | 74 |
colorimetric detection | 74 |
investigated whether | 74 |
functional genomics | 74 |
silver nanoparticles | 74 |
different proteins | 74 |
gene promoter | 74 |
van het | 74 |
mrna level | 74 |
bronchitis virus | 74 |
host factors | 74 |
genes associated | 74 |
virus entry | 74 |
small rnas | 73 |
mammary gland | 73 |
also studied | 73 |
papillomavirus type | 73 |
two decades | 73 |
atp hydrolysis | 73 |
data collection | 73 |
three types | 73 |
protein concentration | 73 |
dna complex | 73 |
gene targeting | 73 |
near future | 73 |
kidney disease | 73 |
resistant staphylococcus | 73 |
antibodies directed | 73 |
biological properties | 73 |
nucleoside analogues | 73 |
years later | 73 |
acute infection | 73 |
mice infected | 73 |
contains two | 73 |
airway epithelia | 73 |
synthetic peptide | 73 |
positive selection | 73 |
viral mrna | 73 |
cell transplant | 73 |
four groups | 73 |
laboratory mice | 73 |
target molecule | 73 |
amplification techniques | 73 |
will need | 73 |
antibody identification | 73 |
using specific | 73 |
significant improvement | 73 |
time course | 73 |
global health | 73 |
wide spectrum | 73 |
animal studies | 72 |
virus strains | 72 |
association studies | 72 |
studies demonstrated | 72 |
receptor antagonist | 72 |
deep sequencing | 72 |
increasing concentrations | 72 |
polyclonal antibody | 72 |
folic acid | 72 |
physical activity | 72 |
coagulation factors | 72 |
interferon response | 72 |
double helix | 72 |
pathological conditions | 72 |
binding capacity | 72 |
small amounts | 72 |
average age | 72 |
day post | 72 |
showed increased | 72 |
gene editing | 72 |
donor screening | 72 |
chemical properties | 72 |
hpv infection | 72 |
recognition receptors | 72 |
beneficial effects | 72 |
information regarding | 72 |
compound heterozygous | 72 |
negative regulator | 72 |
inflammatory disease | 72 |
normal tissues | 72 |
significantly elevated | 72 |
microbial communities | 72 |
month period | 72 |
adenovirus dna | 72 |
hepatic encephalopathy | 72 |
therapeutic effect | 72 |
remains unknown | 72 |
genomic sequence | 72 |
net formation | 72 |
results provide | 72 |
positively correlated | 72 |
receptor signaling | 72 |
conditioned media | 72 |
dna content | 72 |
many patients | 72 |
acquired pneumonia | 72 |
data suggests | 72 |
actin cytoskeleton | 72 |
direct antiglobulin | 72 |
structural studies | 72 |
hours post | 72 |
penton base | 71 |
willebrand factor | 71 |
bacterial strains | 71 |
also developed | 71 |
cell signaling | 71 |
cells within | 71 |
nuclear dna | 71 |
method based | 71 |
survival rates | 71 |
see chapter | 71 |
dependent protein | 71 |
cell tumors | 71 |
replication complex | 71 |
gene function | 71 |
laboratory animal | 71 |
may allow | 71 |
modified vaccinia | 71 |
matrix protein | 71 |
female patient | 71 |
viral loads | 71 |
past decade | 71 |
control study | 71 |
arachidonic acid | 71 |
electrochemical dna | 71 |
viral envelope | 71 |
goat anti | 71 |
potential target | 71 |
systems biology | 71 |
antiviral responses | 71 |
also provide | 71 |
ct scan | 71 |
specific cell | 71 |
environmental conditions | 71 |
protein microarray | 71 |
generated using | 71 |
first reported | 71 |
conditioned medium | 71 |
surface charge | 71 |
type iii | 71 |
fl uorescence | 71 |
signifi cant | 71 |
allows us | 71 |
well documented | 71 |
dynamic range | 71 |
potential applications | 71 |
malignant transformation | 71 |
cell lysate | 71 |
enzyme immunoassay | 71 |
competing interests | 71 |
ml kg | 71 |
proteasomal degradation | 71 |
mouse hepatitis | 71 |
malignant cells | 71 |
i clinical | 71 |
patients infected | 71 |
cancer immunotherapy | 71 |
false negative | 71 |
months post | 71 |
th day | 71 |
last two | 70 |
detection limits | 70 |
fold lower | 70 |
sequence comparison | 70 |
bacterial genomes | 70 |
higher concentrations | 70 |
cell number | 70 |
developed countries | 70 |
candida albicans | 70 |
genetic recombination | 70 |
high cost | 70 |
suppressor gene | 70 |
adult mice | 70 |
curve analysis | 70 |
antibody levels | 70 |
infection may | 70 |
mast cell | 70 |
fold change | 70 |
veterinary medicine | 70 |
emerging viruses | 70 |
treatment groups | 70 |
binding kinetics | 70 |
tumor tissue | 70 |
cytotoxic effects | 70 |
high temperature | 70 |
bact alert | 70 |
experiments showed | 70 |
diarrhea virus | 70 |
cell apoptosis | 70 |
response rate | 70 |
relatively small | 70 |
prion protein | 70 |
negative correlation | 70 |
dawley rats | 70 |
mismatch repair | 70 |
mean value | 70 |
functional studies | 70 |
particular interest | 70 |
protective effects | 70 |
increasing evidence | 70 |
therapeutic approaches | 70 |
sequencing technologies | 70 |
recombinant virus | 70 |
identifi cation | 70 |
type ia | 70 |
natural selection | 70 |
safety profile | 70 |
hsp inhibitors | 70 |
lymphoid cells | 70 |
terminal domains | 70 |
mechanical ventilation | 69 |
may reflect | 69 |
intraepithelial neoplasia | 69 |
mainly due | 69 |
may facilitate | 69 |
pcr reactions | 69 |
ge healthcare | 69 |
taq dna | 69 |
within minutes | 69 |
dependent dna | 69 |
induce apoptosis | 69 |
clinical development | 69 |
preclinical studies | 69 |
independent experiments | 69 |
several genes | 69 |
exogenous dna | 69 |
three independent | 69 |
experimental evidence | 69 |
conventional methods | 69 |
coupled receptor | 69 |
study also | 69 |
vaccine efficacy | 69 |
common cause | 69 |
scid mice | 69 |
common ancestor | 69 |
related proteins | 69 |
may contain | 69 |
adenovirus vector | 69 |
surgical procedures | 69 |
two samples | 69 |
luciferase activity | 69 |
using various | 69 |
three days | 69 |
cardiac hypertrophy | 69 |
control animals | 69 |
rhd gene | 69 |
recombination events | 69 |
stably expressing | 69 |
like protease | 69 |
based biosensor | 69 |
therapeutic approach | 69 |
unfolded protein | 69 |
wt mice | 69 |
study suggests | 69 |
performance liquid | 69 |
adverse event | 69 |
common variable | 69 |
adenosine deaminase | 68 |
five years | 68 |
significantly greater | 68 |
results revealed | 68 |
airway inflammation | 68 |
promising approach | 68 |
rapid diagnosis | 68 |
higher expression | 68 |
direct sequencing | 68 |
liver tissues | 68 |
vaccine production | 68 |
recently shown | 68 |
animal viruses | 68 |
template dna | 68 |
myeloid leukemia | 68 |
alveolar macrophages | 68 |
also determined | 68 |
without affecting | 68 |
respiratory pathogens | 68 |
abo blood | 68 |
hpv dna | 68 |
reperfusion injury | 68 |
routine use | 68 |
modifi cation | 68 |
medical research | 68 |
human pathogens | 68 |
additional studies | 68 |
specific igg | 68 |
short time | 68 |
fluorescent signal | 68 |
ankara university | 68 |
male patient | 68 |
also included | 68 |
genetic code | 68 |
donated blood | 68 |
molecular markers | 68 |
will discuss | 68 |
log copies | 68 |
bile acid | 68 |
using primers | 68 |
national university | 68 |
coronavirus infection | 68 |
starting point | 68 |
dependent kinase | 68 |
biomedical research | 68 |
results suggested | 68 |
colon carcinoma | 68 |
one day | 68 |
node metastases | 68 |
also show | 68 |
von willebrand | 68 |
patients developed | 68 |
specific protein | 68 |
also able | 67 |
molecular typing | 67 |
small bowel | 67 |
molecular beacons | 67 |
study provides | 67 |
basic research | 67 |
cell damage | 67 |
related diseases | 67 |
also involved | 67 |
oxide synthase | 67 |
detection systems | 67 |
primary immune | 67 |
correlation coefficient | 67 |
like cells | 67 |
induces apoptosis | 67 |
decreased expression | 67 |
cell nucleus | 67 |
ray crystallography | 67 |
published data | 67 |
shed light | 67 |
diffuse large | 67 |
differentially methylated | 67 |
functional properties | 67 |
cytometric analysis | 67 |
well defined | 67 |
host proteins | 67 |
prognostic significance | 67 |
lamp assay | 67 |
breast carcinomas | 67 |
buffy coats | 67 |
poorly differentiated | 67 |
pfu ml | 67 |
european countries | 67 |
cancer risk | 67 |
screening test | 67 |
lesser extent | 67 |
umbilical vein | 67 |